German Isentress Case Could Mean More Compulsory Licensing In Europe
Executive Summary
A German court’s decision to uphold a compulsory license allowing Merck & Co to keep on selling its HIV drug Isentress could pave the way for more compulsory licensing in Europe.
You may also be interested in...
Shionogi/Merck HIV Patent Tussle Set To Go Another Round
Shionogi has vowed to appeal a ruling by a court in the UK that a patent relating to HIV integrase inhibitors is invalid, as an ongoing European intellectual property tussle with rival Merck & Co gathers steam.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.